Can you take Mounjaro if you don't have a gallbladder?

Why the gallbladder question comes up with Mounjaro in the first place

A question our prescribers hear most weeks goes something like: "I had my gallbladder out years ago, does that mean Mounjaro's off the table?" The short answer is no, not automatically. But understanding why people ask tells you something useful about how tirzepatide works.

Mounjaro activates two gut-hormone receptors simultaneously (GIP and GLP-1) and one effect of that dual action is a significant slowing of gastric emptying. Food leaves the stomach more gradually, appetite falls, and bile from the liver, which now drains directly into the small intestine after cholecystectomy rather than being stored and concentrated in the gallbladder, flows in a more continuous pattern. That continuous drip is actually closer to normal digestion than the concentrated boluses released by an intact gallbladder, which is partly why many post-cholecystectomy patients do not experience worse GI symptoms on tirzepatide than the general treatment population.

What the NHS medicines page for tirzepatide does make clear is that biliary problems (gallstones, cholecystitis and related conditions) are listed among the known side effects of treatment. That listing applies to people with a gallbladder; without one, the gallstone risk itself disappears, but other biliary considerations remain worth a conversation, and if you want a thorough answer to whether you can take Mounjaro with no gallbladder in the UK, that dedicated page walks through the clinical picture in full. Tirzepatide carries a Black Triangle (▼) status, meaning the MHRA continues to gather safety data, and prescribers factor that into every assessment.

The digestive changes that matter most after cholecystectomy

Living without a gallbladder already changes how your body handles fat. Bile, which breaks down dietary fat, flows continuously rather than being released in concentrated bursts at mealtimes. Many people adjust within months; others find fatty meals trigger loose stools or cramping for years.

Tirzepatide's GI side-effect profile (nausea, loose stools, stomach discomfort) overlaps with symptoms some post-cholecystectomy patients already experience, so it can be harder to distinguish new drug-related effects from existing digestive patterns. That is not a reason to avoid treatment; it is a reason to be clear with your prescriber about your baseline. If you already manage post-cholecystectomy diarrhoea, they may want to titrate more cautiously or monitor more closely, particularly in the early weeks.

The full side-effect profile for Mounjaro covers the range of GI effects in more detail, and the timing strategies for managing nausea are worth knowing before you start. Both become more useful when you understand your own digestive baseline.

If you notice that your stools change in a way that concerns you (particularly if they are very dark) that is worth reporting to your clinical team promptly. Dark or black stools on GLP-1 treatment occasionally flag an unrelated GI issue that needs attention; this page on stool changes during Mounjaro explains what to look out for.

When to get medical help, and what warrants an emergency call

Tirzepatide has been associated with pancreatitis: rare, but serious. In January 2026 the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as a known risk across GLP-1 class medicines. The warning sign to act on immediately is severe, persistent stomach pain (particularly pain that radiates through to your back) with or without vomiting. That pattern needs emergency assessment, not a wait-and-see approach.

For post-cholecystectomy patients specifically, upper-right abdominal pain can sometimes be attributed to "phantom gallbladder" sensations or bile duct issues; do not assume discomfort on Mounjaro is one of those. If pain is severe, go to A&E or call 999. Your prescriber and the Mounjaro Patient Information Leaflet are your first reference for anything that feels outside your normal range.

Signs of dehydration from persistent vomiting or diarrhoea also need prompt attention: dizziness, very dark urine, inability to keep fluids down for more than 24 hours. These are manageable if caught early and much harder to manage if left.

The MHRA's Yellow Card scheme lets you report suspected side effects directly, your report contributes to the ongoing safety monitoring of tirzepatide and helps protect future patients. You can report as a patient; you do not need to go through a clinician to do so.

Making the decision: what the consultation actually resolves

The decision about whether Mounjaro is appropriate for you after gallbladder removal is a clinical one, not one a web page can make. What a consultation does is give a GPhC-registered prescriber the full picture: when the cholecystectomy was done, how your digestion settled afterwards, any ongoing biliary symptoms, your current BMI and relevant conditions, and any other medicines you take.

At nume, that consultation is reviewed the same day by a real clinician (not software) and the review covers exactly this kind of nuance. You can read more about how Mounjaro works and who it's licensed for, or explore all treatment options if you're weighing up which medicine to ask about. Our clinical team is available for aftercare questions seven days a week once treatment begins.

If you're at the stage of checking your eligibility, the broader overview of Mounjaro and gallbladder considerations covers the general clinical picture. And if you're a transfer patient already established on tirzepatide who's had a recent cholecystectomy, flag that change at your next review, treatment can continue in many cases, but your prescriber should know.